A framework for understanding and targeting residual disease in oncogene-driven solid cancers

Nature Medicine

Volumn 22, Issue 5, 2016, Pages 472-478

  Bivona, Trever G ^a,b   Doebele, Robert C ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOMODULATING AGENT;

ADAPTATION; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL (TOPIC); DISEASE ELIMINATION; GENE TARGETING; HUMAN; MINIMAL RESIDUAL DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR CELL; DRUG RESISTANCE; GENETICS; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; NEOPLASM, RESIDUAL; NEOPLASMS; ONCOGENE; PROCEDURES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASM, RESIDUAL; NEOPLASMS; ONCOGENES;

EID: 84966290869     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4091     Document Type: Review

References (84)

1. Collins, F.S. & Varmus, H. A new initiative on precision medicine. N. Engl. J. Med. 372, 793-795 (2015).
2. Varmus, H. Ten years on - the human genome and medicine. N. Engl. J. Med. 362, 2028-2029 (2010).
3. Sawyers, C.L. The 2011 Gordon Wilson lecture: overcoming resistance to targeted cancer drugs. Trans. Am. Clin. Climatol. Assoc. 123, 114-123, discussion 123-125 (2012).
4. Sawyers, C.L. Lessons learned from the development of kinase inhibitors. Clin. Adv. Hematol. Oncol. 7, 588-589 (2009).
5. Sawyers, C.L. Shifting paradigms: the seeds of oncogene addiction. Nat. Med. 15, 1158-1161 (2009).
6. de Bono, J.S. & Ashworth, A. Translating cancer research into targeted therapeutics. Nature 467, 543-549 (2010).
7. Garraway, L.A. & Jänne, P.A. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov. 2, 214-226 (2012).
8. Blumenthal, G.M. et al. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses. J. Clin. Oncol. 33, 1008-1014 (2015).
9. Boxer, R.B., Jang, J.W., Sintasath, L. & Chodosh, L.A. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell 6, 577-586 (2004).
10. Zhang, Z. et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 44, 852-860 (2012).
11. Hrustanovic, G. et al. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat. Med. 21, 1038-1047 (2015).
12. Yu, H.A. et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 19, 2240-2247 (2013).
13. Van Allen, E.M. et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 4, 94-109 (2014).
14. Ahronian, L.G. et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov. 5, 358-367 (2015).
15. Poulikakos, P.I., Zhang, C., Bollag, G., Shokat, K.M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF. Nature 464, 427-430 (2010).
16. Lito, P., Rosen, N. & Solit, D.B. Tumor adaptation and resistance to RAF inhibitors. Nat. Med. 19, 1401-1409 (2013).
17. V600E. Nature 480, 387-390 (2011).
18. V600E melanomas. Cancer Cell 22, 668-682 (2012).
19. V600E inhibition through feedback activation of EGFR. Nature 483, 100-103 (2012).
20. Alizadeh, A.A. et al. Toward understanding and exploiting tumor heterogeneity. Nat. Med. 21, 846-853 (2015).
21. de Bruin, E.C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251-256 (2014).
22. Hiley, C., de Bruin, E.C., McGranahan, N. & Swanton, C. Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome Biol. 15, 453 (2014).
23. Burrell, R.A. & Swanton, C. Tumor heterogeneity and the evolution of polyclonal drug resistance. Mol. Oncol. 8, 1095-1111 (2014).
24. Turke, A.B. et al. Preexistence and clonal selection of MET amplification in EGFR-mutant NSCLC. Cancer Cell 17, 77-88 (2010).
25. T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin. Cancer Res. 17, 1160-1168 (2011).
26. Lin, L. et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat. Genet. 47, 250-256 (2015).
27. Janku, F. et al. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One 6, e22769 (2011).
28. Hata, A.N. et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22, 262-269 (2016).
29. Müller, J. et al. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat. Commun. 5, 5712 (2014).
30. Straussman, R. et al. Tumor microenvironment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504 (2012).
31. Blakely, C.M. et al. NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Rep. 11, 98-110 (2015).
32. Sharma, S.V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80 (2010).
33. Lee, H.J. et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 26, 207-221 (2014).
34. Haq, R. et al. Oncogenic BRAF regulates oxidative metabolism via PGC-1α and MITF. Cancer Cell 23, 302-315 (2013).
35. Wilson, T.R. et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509 (2012).
36. Obenauf, A.C. et al. Therapy-induced tumor secretomes promote resistance and tumor progression. Nature 520, 368-372 (2015).
37. Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599 (2010).
38. Szmulewitz, R.Z. & Ratain, M.J. Vemurafenib oral bioavailability: an insoluble problem. J. Clin. Pharmacol. 54, 375-377 (2014).
39. Undevia, S.D., Gomez-Abuin, G. & Ratain, M.J. Pharmacokinetic variability of anticancer agents. Nat. Rev. Cancer 5, 447-458 (2005).
40. Neesse, A., Algül, H., Tuveson, D.A. & Gress, T.M. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut 64, 1476-1484 (2015).
41. Jain, R.K. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26, 605-622 (2014).
42. Jänne, P.A. et al. Phase 1 safety and pharmacokinetic study of the PI3K-mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors. J. Thorac. Oncol. 9, 316-323 (2014).
43. Lin, N.U. Targeted therapies in brain metastases. Curr. Treat. Options Neurol. 16, 276 (2014).
44. Thompson, C.B. Targeting the anti-apoptotic signaling pathway. Clin. Adv. Hematol. Oncol. 7, 819-822 (2009).
45. Shaw, A.T. et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 370, 1189-1197 (2014).
46. Sequist, L.V. et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 372, 1700-1709 (2015).
47. Jänne, P.A. et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 372, 1689-1699 (2015).
48. V600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J. Clin. Oncol. 32, 3697-3704 (2014).
49. Charakidis, M. & Boyer, M. Targeting MET and EGFR in NSCLC - what can we learn from the recently reported phase 3 trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer? Transl. Lung Cancer Res. 3, 395-396 (2014).
50. Riely, G.J. et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin. Cancer Res. 13, 5150-5155 (2007).
51. Wagle, N. et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF-MEK inhibition. Cancer Discov. 4, 61-68 (2014).
52. V600 mutations. N. Engl. J. Med. 367, 1694-1703 (2012).
53. Long, G.V. et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 371, 1877-1888 (2014).
54. Bhang, H.E. et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat. Med. 21, 440-448 (2015).
55. Bozic, I. et al. Evolutionary dynamics of cancer in response to targeted combination therapy. eLife 2, e00747 (2013).
56. Schwaederle, M. et al. On the road to precision cancer medicine: analysis of genomic biomarker actionability in 439 patients. Mol. Cancer Ther. 14, 1488-1494 (2015).
57. Crystal, A.S. et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346, 1480-1486 (2014).
58. Gao, D. et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 159, 176-187 (2014).
59. Gingras, I., Salgado, R. & Ignatiadis, M. Liquid biopsy: will it be the 'magic tool' for monitoring response of solid tumors to anticancer therapies? Curr. Opin. Oncol. 27, 560-567 (2015).
60. Li, X. et al. Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nat. Med. 20, 769-777 (2014).
61. Karthaus, W.R. et al. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell 159, 163-175 (2014).
62. T790-positive cancers with a third-generation EGFR inhibitor. Cancer Discov. 5, 713-722 (2015).
63. Nakasone, E.S. et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 21, 488-503 (2012).
64. Mayer, R.J. et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N. Engl. J. Med. 331, 896-903 (1994).
65. Coombs, C.C., Tallman, M.S. & Levine, R.L. Molecular therapy for acute myeloid leukemia. Nat. Rev. Clin. Oncol. (2015).
66. Condeelis, J. & Weissleder, R. In vivo imaging in cancer. Cold Spring Harb. Perspect. Biol. 2, a003848 (2010).
67. Doebele, R.C. et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small-cell lung cancer. Clin. Cancer Res. 18, 1472-1482 (2012).
68. Van Allen, E.M. et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat. Med. 20, 682-688 (2014).
69. De Silva, N. et al. Molecular effects of lapatinib in the treatment of HER2-overexpressing oesophago-gastric adenocarcinoma. Br. J. Cancer 113, 1305-1312 (2015).
70. T790M. Nat. Med. 21, 560-562 (2015).
71. Siravegna, G. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 21, 795-801 (2015).
72. Murtaza, M. et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108-112 (2013).
73. Behbehani, G.K. et al. Mass cytometric functional profiling of acute myeloid leukemia defines cell-cycle and immunophenotypic properties that correlate with known responses to therapy. Cancer Discov. 5, 988-1003 (2015).
74. Macosko, E.Z. et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell 161, 1202-1214 (2015).
75. Larkin, J. et al. Combined nivolumab and ipilimumab, or monotherapy, in untreated melanoma. N. Engl. J. Med. 373, 23-34 (2015).
76. Sequist, L.V. et al. Randomized phase 2 study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J. Clin. Oncol. 29, 3307-3315 (2011).
77. Spigel, D.R. et al. Final efficacy results from OAM4558g, a randomized phase 2 study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC (ASCO Annual Meeting) 7505 (American Society of Clinical Oncology, Alexandria, Virginia, USA, 2011).
78. Price, K.A. et al. Phase 2 trial of gefitinib and everolimus in advanced non-small-cell lung cancer. J. Thorac. Oncol. 5, 1623-1629 (2010).
79. Witta, S.E. et al. Randomized phase 2 trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J. Clin. Oncol. 30, 2248-2255 (2012).
80. Johnson, M.L. et al. Phase 1/2 study of HSP90 inhibitor AUY922 and erlotinib for EGFR-mutant lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. J. Clin. Oncol. 33, 1666-1673 (2015).
81. V600E mutated (mut) metastatic non-small-cell lung cancer (NSCLC) (ASCO Annual Meeting) 8006 (American Society of Clinical Oncology, Alexandria, Virginia, USA, 2011).
82. Yaeger, R. et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin. Cancer Res. 21, 1313-1320 (2015).
83. Hurvitz, S.A. et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomized, double-blind, multicenter trial. Lancet Oncol. 16, 816-829 (2015).
84. Swain, S.M. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N. Engl. J. Med. 372, 724-734 (2015).